# Clinical Trials Data BRAF - Document 20

# Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study

## Clinical Trial: https://clinicaltrials.gov/study/NCT02038348

"eligibilityCriteria": "Inclusion Criteria:\n\n\* B-RAF mutated metastatic melanoma.\n\* Reference imaging \\<1 month inclduing a whole body CT and 18F-FDG.\n\* At least one metastatic lesion at least with a diameter\\> 10 mm on CT.\n\* To which the staff has proposed, a B-RAF inhibitor in first-line treatment\n\* Signed informed consent.\n\nExclusion Criteria:\n\n\* Minor subject.\n\* Subject diabetic.\n\* Women of childbearing potential without effective contraception, with positive pregnancy test.\n\* Other known active cancer.\n\* No affiliation to a social security (beneficiary or assignee).",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with a BRAF gene mutation would \*potentially\* be eligible for this trial. The inclusion criteria explicitly state "B-RAF mutated metastatic melanoma."  
  
However, meeting that single criterion is not enough. The patient must \*also\* meet all other inclusion criteria (recent imaging, measurable lesion, recommended for BRAF inhibitor treatment, and signed consent) and \*not\* meet any of the exclusion criteria (minor, diabetic, pregnant or potential for pregnancy without contraception, other active cancer, no social security affiliation).